Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP410924.RApXjM_mgfqHN4vinLYHjvGTpB66fWlS1Awc6GIYHRR5Y130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP410924.RApXjM_mgfqHN4vinLYHjvGTpB66fWlS1Awc6GIYHRR5Y130_assertion type Assertion NP410924.RApXjM_mgfqHN4vinLYHjvGTpB66fWlS1Awc6GIYHRR5Y130_head.
- NP410924.RApXjM_mgfqHN4vinLYHjvGTpB66fWlS1Awc6GIYHRR5Y130_assertion description "[Amplification of ERBB-2 was detected in 14 out of 63 (22%) cases of breast carcinoma, in 1 out of 23 patients with ovarian cancers, in 1 out of 19 cases of colon carcinoma and in 1 out of 27 patients with thyroid cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP410924.RApXjM_mgfqHN4vinLYHjvGTpB66fWlS1Awc6GIYHRR5Y130_provenance.
- NP410924.RApXjM_mgfqHN4vinLYHjvGTpB66fWlS1Awc6GIYHRR5Y130_assertion evidence source_evidence_literature NP410924.RApXjM_mgfqHN4vinLYHjvGTpB66fWlS1Awc6GIYHRR5Y130_provenance.
- NP410924.RApXjM_mgfqHN4vinLYHjvGTpB66fWlS1Awc6GIYHRR5Y130_assertion SIO_000772 1349430 NP410924.RApXjM_mgfqHN4vinLYHjvGTpB66fWlS1Awc6GIYHRR5Y130_provenance.
- NP410924.RApXjM_mgfqHN4vinLYHjvGTpB66fWlS1Awc6GIYHRR5Y130_assertion wasDerivedFrom befree-2016 NP410924.RApXjM_mgfqHN4vinLYHjvGTpB66fWlS1Awc6GIYHRR5Y130_provenance.
- NP410924.RApXjM_mgfqHN4vinLYHjvGTpB66fWlS1Awc6GIYHRR5Y130_assertion wasGeneratedBy ECO_0000203 NP410924.RApXjM_mgfqHN4vinLYHjvGTpB66fWlS1Awc6GIYHRR5Y130_provenance.